BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today upcoming presentations, ...
We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks 2nd on this list. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a relatively ...
Pfizer said on Tuesday that it has reached settlement agreements with three generic manufacturers — Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd. — resolving patent-infringement lawsuits over ...
BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...
Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...
Pharmaceutical Technology on MSN
Pfizer protects $6.4bn heart disease blockbuster from generics, for now
Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.
The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug ...
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...
Adds Pfizer statement. BridgeBio (BBIO) fell 1.3% after originally gaining 11% as a court filing disclosed a settlement in a ...
Mortgage origination remains highly volatile. Macroeconomic factors outside of Rocket's control could lead to a sharp reduction in revenue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results